This article was originally published here
Asian J Androl. November 2, 2021. doi: 10.4103 / aja202166. Online ahead of print.
The aim of this study was to investigate the incidence of erectile dysfunction (ED) in patients with non-muscle invasive bladder cancer (NMIBC) before and after transurethral resection (TUR) in China. Clinical data from 165 male patients with NMIBC who received adjuvant intravesical chemotherapy after TUR at Neijiang First People’s Hospital (Neijiang, China) between January 2010 and June 2019 were retrospectively reviewed. The sexual function of these patients was assessed before and 1.5 years after the initial TUR by the International Index of Erectile Function-5 (IIEF-5). An age-specific sub-analysis was performed among patients: erectile dysfunction in group 1 were 15.8% and 52.6%, and those in group 2 were 54.1% and 61.0 %, respectively. The difference between the groups was statistically significant at the preoperative stage (15.8% vs 54.1%, p = 0.002) but not at the postoperative stage (52.6% vs 61.0%, p = 0.562). Compared to the preoperative stage, the incidence of postoperative ED was significantly increased in group 1 (15.8% vs 52.6%, p = 0.017) but not in group 2 (54.1% vs 61 , 0%, p = 0.345). In conclusion, the incidence of erectile dysfunction increased in male NMIBC patients under 45 years after TUR in China. These patients should be offered professional counseling during the follow-up period.
PMID: 34747726 | DOI: 10.4103 / aja202166